PLRZ Stock Overview
A biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Polyrizon Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.91 |
| 52 Week High | US$1.97 |
| 52 Week Low | US$0.77 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| PLRZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.7% | 4.3% | 1.6% |
| 1Y | n/a | 18.8% | 32.3% |
Return vs Industry: Insufficient data to determine how PLRZ performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PLRZ performed against the US Market.
Price Volatility
| PLRZ volatility | |
|---|---|
| PLRZ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PLRZ's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PLRZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2 | Tomer Izraeli | www.polyrizon-biotech.com |
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza.
Polyrizon Ltd. Fundamentals Summary
| PLRZ fundamental statistics | |
|---|---|
| Market cap | US$3.00m |
| Earnings (TTM) | -US$1.07m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs PLRZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLRZ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.07m |
| Earnings | -US$1.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 68.0% |
How did PLRZ perform over the long term?
See historical performance and comparison